Manufacturing Chemist Stand Side with C2 Pharma

Published: 6-Nov-2023 Featured companies: C-squared Pharma
Manufacturing Ingredients Marketing

At the recent CPHI WorldWide event in Barcelona, Spain, CEO of C2 Pharma, Andrew Badrot, talked exclusively to Manufacturing Chemist Stand Side

As well as covering a range of topics, from staying ahead of the competition to fostering a culture of quality, Andrew also took a crystal ball approach to what's happening in the industry. He talked about trends and upcoming innovations, how they will impact how the company operates ... and what customers can expect from C2 Pharma in 2024.

Manufacturing Chemist Stand Side...

'Manufacturing Chemist Stand Side' is a series of exclusive video interviews with leading companies in the pharmaceutical industry, conducted during key market events by our award-winning B2B team.

For more information on how you can be part of 'Manufacturing Chemist Stand Side' contact Don Phares on +44 207 193 3219 or via email: don@hpcimedia.com.

Featured companies

C2 PHARMA is an European pharmaceutical group established in 2014. It manufactures and distributes active pharmaceutical ingredients (APls) and complex chemical compounds...
See more

You may also like

Ingredients

C2 PHARMA announces upcoming launch of new oxybuprocaine hydrochloride API

Read more
C2 PHARMA excited to announce the upcoming launch of its new API, oxybuprocaine HCL, an ingredient that will be manufactured by manufacturing partner Laurus Labs

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  3. ChargePoint invest in a single-use manufacturing facility to expand product line The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
  4. Miltenyi Biotec and MiLaboratories collaborate to advance next-generation therapies Miltenyi Biotec will commercialise MiLaboratories' RNA kit technology for immune sequencing, facilitating advances in the field of personalised medicine
  5. Innovation in generics: increased efficiency through peptide API synthesis expertise Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues

Relevant companies

See more

Upcoming event

ASGCT Annual Meeting 2024

7-11 May, 2024 | Meeting | Portland, OR See all

You may also like

Ingredients

C2 PHARMA announces upcoming launch of new oxybuprocaine hydrochloride API

C2 PHARMA excited to announce the upcoming launch of its new API, oxybuprocaine HCL, an ingredient that will be manufactured by manufacturing partner Laurus Labs
Ingredients

C2 Pharma to participate in DCAT Week 2024

The C2 PHARMA team will be located in the Benjamin hotel in Suite 2202
Ingredients

C2 PHARMA receives DMF approval in China for pilocarpine nitrate

C2 PHARMA announces the approval of a C-DMF for pilocarpine nitrate — granted on 30 October 2023 — an API manufactured by our Brazilian partner Anidro do Brasil
Ingredients

C2 PHARMA expands API portfolio with global regulatory access ahead of CPHI Barcelona

C2 PHARMA along with their affiliates, Logistics4PHARMA and ASM Research Chemicals, will be exhibiting in the Integrated Pharma Hall for the first time at booth 4D49
Manufacturing

C2 Pharma focuses on ophthalmic APIs at CPHI

Located at stand 4D49, the company looks forward to informing customers about its expanded logistics facility in Frankfurt and what its unique DEV Pack approach can do to streamline API processes
Manufacturing

EDQM grants C2 Pharma CEP approval for commercial sale of cyclopentolate hydrochloride

The manufacturing process was documented by ASM in a development pack (dev-pack) and transferred to Indian manufacturing partners, Laurus Labs
Distribution

C2 Pharma reveals C-DMF approval of its API

This milestone comes after a challenging three-year journey, due to "global disruptions caused by the Covid pandemic"
Subscribe now